Roth MKM Maintains Buy Rating for GT Biopharma with $11 Price Target

Roth MKM maintains a Buy rating on GT Biopharma (GTBP) with a price target of $11.00. Jonathan Aschoff, the analyst, has a success rate of 29.93% and an average return of -17.7%. The company reported a GAAP net loss of $776 thousand for Q1, compared to a loss of $2.27 million last year. The overall analyst consensus is a Moderate Buy rating with an average price target of $11.00.

GT Biopharma, Inc. (GTBP) has been under the spotlight recently, with a notable change in its stock price and analyst ratings. On May 16, 2025, the stock price of GTBP fell by -0.446%, from $2.24 to $2.23. This decline follows a broader trend, with the stock falling in 6 of the last 10 trading days and a cumulative decrease of -4.29% over this period [1].

The stock's performance has been influenced by several factors, including technical indicators and analyst ratings. Roth MKM maintains a Buy rating on GTBP with a price target of $11.00. Jonathan Aschoff, the analyst behind this rating, has a success rate of 29.93% and an average return of -17.7%. Despite this, the overall analyst consensus is a Moderate Buy rating, with an average price target of $11.00 [2].

Technical analysis suggests that GTBP is moving within a wide and horizontal trend, with a 90% probability of trading between $2.10 and $2.50 by the end of the 3-month period. However, the stock has been showing signs of weakness, with few to no technical positive signals. Moving averages are indicating a sell signal, and there is a general sell signal from the relationship between the long-term and short-term averages [1].

The company reported a GAAP net loss of $776 thousand for Q1, compared to a loss of $2.27 million last year. This financial performance, combined with the technical indicators, suggests that GTBP is a high-risk investment. The stock is expected to open at $2.24 on May 19, 2025, with a possible trading interval of +/-$0.139 (+/-6.21%) up or down from the last closing price. However, the stock is closer to support at $2.20 than resistance at $2.30, indicating a potential for profit before reaching the first resistance level [1].

Given the current circumstances, GT Biopharma, Inc. (GTBP) is a hold candidate rather than a buy. The stock holds several negative signals, and the risk/reward ratio is not favorable. Investors should monitor the stock closely and await further developments before making any investment decisions. The stock's performance in the coming weeks will be crucial in determining its future trajectory.

References:
[1] https://stockinvest.us/stock/GTBP
[2] https://quantisnow.com/company/GTBP